|
1
|
Ding L, Wo L, Du Z, Tang L, Song Z and Dou
X: Danshen protects against early-stage alcoholic liver disease in
mice via inducing PPARα activation and subsequent 4-HNE
degradation. PLoS One. 12:e01863572017. View Article : Google Scholar
|
|
2
|
Singal AK, Kamath PS, Gores GJ and Shah
VH: Alcoholic hepatitis: Current challenges and future directions.
Clin Gastroenterol Hepatol. 12:555–564; quiz e31-e32. 2014.
View Article : Google Scholar :
|
|
3
|
Gao B and Bataller R: Alcoholic liver
disease: Pathogenesis and new therapeutic targets.
Gastroenterology. 141:1572–1585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bataller R and Gao B: Liver fibrosis in
alcoholic liver disease. Semin Liver Dis. 35:146–156. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Voican CS, Louvet A, Trabut JB,
Njiké-Nakseu M, Dharancy S, Sanchez A, Corouge M, Lamouri K, Lebrun
A, Balian A, et al: Transient elastography alone and in combination
with FibroTest® for the diagnosis of hepatic fibrosis in
alcoholic liver disease. Liver Int. 37:1697–1705. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roh YS and Seki E: Toll-like receptors in
alcoholic liver disease, non-alcoholic steatohepatitis and
carcinogenesis. J Gastroenterol Hepatol. 28(Suppl 1): S38–S42.
2013. View Article : Google Scholar
|
|
7
|
Devi BG, Henderson GI, Frosto TA and
Schenker S: Effect of ethanol on rat fetal hepatocytes: Studies on
cell replication, lipid peroxidation and glutathione. Hepatology.
18:648–659. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Olguín-Martínez M, Hernández-Espinosa DR
and Hernández- Muñoz R: High α-tocopherol dosing increases lipid
metabolism by changing redox state in damaged rat gastric mucosa
and liver after ethanol treatment. Clin Sci (Lond). 132:1257–1272.
2018. View Article : Google Scholar
|
|
9
|
Li YL, Wu J, Wei D, Zhang DW, Feng H, Chen
ZN and Bian H: Newcastle disease virus represses the activation of
human hepatic stellate cells and reverses the development of
hepatic fibrosis in mice. Liver Int. 29:593–602. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Higashi T, Friedman SL and Hoshida Y:
Hepatic stellate cells as key target in liver fibrosis. Adv Drug
Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu HX, Yao Y, Bu FT, Chen Y, Wu YT, Yang
Y, Chen X, Zhu Y, Wang Q, Pan XY, et al: Blockade of YAP alleviates
hepatic fibrosis through accelerating apoptosis and reversion of
activated hepatic stellate cells. Mol Immunol. 107:29–40. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andueza A, Garde N, García-Garzón A,
Ansorena E, López-Zabalza MJ, Iraburu MJ, Zalba G and
Martínez-Irujo JJ: NADPH oxidase 5 promotes proliferation and
fibrosis in human hepatic stellate cells. Free Radic Biol Med.
126:15–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hartmann P and Tacke F: Tiny RNA with
great effects: miR-155 in alcoholic liver disease. J Hepatol.
64:1214–1216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bala S, Csak T, Saha B, Zatsiorsky J,
Kodys K, Catalano D, Satishchandran A and Szabo G: The
pro-inflammatory effects of miR-155 promote liver fibrosis and
alcohol-induced steatohepa-titis. J Hepatol. 64:1378–1387. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leti F, Malenica I, Doshi M, Courtright A,
Van Keuren-Jensen K, Legendre C, Still CD, Gerhard GS and DiStefano
JK: High-throughput sequencing reveals altered expression of
hepatic microRNAs in nonalcoholic fatty liver disease-related
fibrosis. Transl Res. 166:304–314. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trionfini P and Benigni A: MicroRNAs as
master regulators of glomerular function in health and disease. J
Am Soc Nephrol. 28:1686–1696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gailhouste L, Gomez-Santos L, Hagiwara K,
Hatada I, Kitagawa N, Kawaharada K, Thirion M, Kosaka N, Takahashi
RU, Shibata T, et al: miR-148a plays a pivotal role in the liver by
promoting the hepatospecific phenotype and suppressing the
invasiveness of transformed cells. Hepatology. 58:1153–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jung KH, Zhang J, Zhou C, Shen H, Gagea M,
Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK and Beretta L:
Differentiation therapy for hepatocellular carcinoma: Multifaceted
effects of miR-148a on tumor growth and phenotype and liver
fibrosis. Hepatology. 63:864–879. 2016. View Article : Google Scholar :
|
|
20
|
Bhattacharya S, Chalk AM, Ng AJ, Martin
TJ, Zannettino AC, Purton LE, Lu J, Baker EK and Walkley CR:
Increased miR-155-5p and reduced miR-148a-3p contribute to the
suppression of osteosarcoma cell death. Oncogene. 35:5282–5294.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Liang Z, Xu X, Li J, Zhu Y, Meng
S, Li S, Wang S, Xie B, Ji A, et al: miR-148a-3p represses
proliferation and EMT by establishing regulatory circuits between
ERBB3/AKT2/ c-myc and DNMT1 in bladder cancer. Cell Death Dis.
7:e25032016. View Article : Google Scholar
|
|
22
|
Bellissimo T, Russo E, Ganci F, Vico C,
Sacconi A, Longo F, Vitolo D, Anile M, Disio D, Marino M, et al:
Circulating miR-21-5p and miR-148a-3p as emerging non-invasive
biomarkers in thymic epithelial tumors. Cancer Biol Ther. 17:79–82.
2016. View Article : Google Scholar :
|
|
23
|
Chen W, Zhao W, Yang A, Xu A, Wang H, Cong
M, Liu T, Wang P and You H: Integrated analysis of microRNA and
gene expression profiles reveals a functional regulatory module
associated with liver fibrosis. Gene. 636:87–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Z, Wang J, Zeng Q, Hu C, Zhang J, Wang
H, Yan J, Li H and Yu Z: Long noncoding RNA HOTTIP promotes mouse
hepatic stellate cell activation via downregulating miR-148a. Cell
Physiol Biochem. 51:2814–2828. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu J, Luo Z, Pan Y, Zheng W, Li W, Zhang
Z, Xiong P, Xu D, Du M, Wang B, et al: H19/miR-148a/USP4 axis
facilitates liver fibrosis by enhancing TGF-β signaling in both
hepatic stellate cells and hepatocytes. J Cell Physiol.
234:9698–9710. 2019. View Article : Google Scholar
|
|
26
|
Liu XY, He YJ, Yang QH, Huang W, Liu ZH,
Ye GR, Tang SH and Shu JC: Induction of autophagy and apoptosis by
miR-148a through the sonic hedgehog signaling pathway in hepatic
stellate cells. Am J Cancer Res. 5:2569–2589. 2015.PubMed/NCBI
|
|
27
|
Scheving LA, Zhang X, Threadgill DW and
Russell WE: Hepatocyte ERBB3 and EGFR are required for maximal
CCl4-induced liver fibrosis. Am J Physiol Gastrointest Liver
Physiol. 311:G807–G816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang
T, Zhou X, Cao T, Wang B, Shi H and Wang R: Hepatitis B virus X
protein reduces the stability of Nrdp1 to up-regulate ErbB3 in
hepatocellular carcinoma cells. Tumour Biol. 37:10375–10382. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scheving LA, Zhang X, Stevenson MC,
Weintraub MA, Abbasi A, Clarke AM, Threadgill DW and Russell WE:
Loss of hepatocyte ERBB3 but not EGFR impairs
hepatocarcinogen-esis. Am J Physiol Gastrointest Liver Physiol.
309:G942–G954. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li G, Zhang W, Gong L and Huang X:
MicroRNA 125a-5p inhibits cell proliferation and induces apoptosis
in hepatitis B virus-related hepatocellular carcinoma by
downregulation of ErbB3. Oncol Res. 27:449–458. 2019. View Article : Google Scholar
|
|
31
|
Shi J: Regulatory networks between
neurotrophins and miRNAs in brain diseases and cancers. Acta
Pharmacol Sin. 36:149–157. 2015. View Article : Google Scholar :
|
|
32
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar :
|
|
33
|
Ni YH, Huo LJ and Li TT: Antioxidant axis
Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22.
World J Gastroenterol. 23:2002–2011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma X, Luo Q, Zhu H, Liu X, Dong Z, Zhang
K, Zou Y, Wu J, Ge J and Sun A: Aldehyde dehydrogenase 2 activation
ameliorates CCl4-induced chronic liver fibrosis in mice
by up-regulating Nrf2/HO-1 antioxidant pathway. J Cell Mol Med.
22:3965–3978. 2018. View Article : Google Scholar :
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
36
|
Yuan DZ, Yu LL, Qu T, Zhang SM, Zhao YB,
Pan JL, Xu Q, He YP, Zhang JH and Yue LM: Identification and
characterization of progesterone- and estrogen-regulated MicroRNAs
in mouse endometrial epithelial cells. Reprod Sci. 22:223–234.
2015. View Article : Google Scholar :
|
|
37
|
Zhao F, Xu G, Zhou Y, Wang L, Xie J, Ren
S, Liu S and Zhu Y: MicroRNA-26b inhibits hepatitis B virus
transcription and replication by targeting the host factor CHORDC1
protein. J Biol Chem. 289:35029–35041. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Osaki K, Shimizu Y, Yamamoto T, Miyake F,
Kondo S and Yamaguchi H: Improvement of liver function by the
administration of oyster extract as a dietary supplement to
habitual alcohol drinkers: A pilot study. Exp Ther Med. 10:705–710.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Y, Huang F, Wang J, Peng L and Luo
H: MiR-15b mediates liver cancer cells proliferation through
targeting BCL-2. Int J Clin Exp Pathol. 8:15677–15683. 2015.
|
|
40
|
Roderburg C and Trautwein C: Cell-specific
functions of miRNA in the liver. J Hepatol. 66:655–656. 2017.
View Article : Google Scholar
|
|
41
|
Pan L, Huang S, He R, Rong M, Dang Y and
Chen G: Decreased expression and clinical significance of miR-148a
in hepatocellular carcinoma tissues. Eur J Med Res. 19:682014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cheng L, Zhu Y, Han H, Zhang Q, Cui K,
Shen H, Zhang J, Yan J, Prochownik E and Li Y: MicroRNA-148a
deficiency promotes hepatic lipid metabolism and
hepatocarcinogenesis in mice. Cell Death Dis. 8:e29162017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bala S and Szabo G: MicroRNA signature in
alcoholic liver disease. Int J Hepatol. 2012:4982322012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mimura S, Iwama H, Kato K, Nomura K,
Kobayashi M, Yoneyama H, Miyoshi H, Tani J, Morishita A, Himoto T,
et al: Profile of microRNAs associated with aging in rat liver. Int
J Mol Med. 34:1065–1072. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Roderburg C, Benz F, Vargas Cardenas D,
Koch A, Janssen J, Vucur M, Gautheron J, Schneider AT, Koppe C,
Kreggenwinkel K, et al: Elevated miR-122 serum levels are an
independent marker of liver injury in inflammatory diseases. Liver
Int. 35:1172–1184. 2015. View Article : Google Scholar
|
|
46
|
Lv Y, Zhang B, Xing G, Wang F and Hu Z:
Protective effect of naringenin against acetaminophen-induced acute
liver injury in metallothionein (MT)-null mice. Food Funct.
4:297–302. 2013. View Article : Google Scholar
|
|
47
|
Rahim SM, Taha EM, Al-janabi MS, Al-douri
BI, Simon KD and Mazlan AG: Hepatoprotective effect of cymbopogon
citratus aqueous extract against hydrogen peroxide-induced liver
injury in male rats. Afr J Tradit Complement Altern Med.
11:447–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ferriero R, Nusco E, De Cegli R, Carissimo
A, Manco G and Brunetti-Pierri N: Pyruvate dehydrogenase complex
and lactate dehydrogenase are targets for therapy of acute liver
failure. J Hepatol. 69:325–335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Oh Y, Park O, Swierczewska M, Hamilton JP,
Park JS, Kim TH, Lim SM, Eom H, Jo DG, Lee CE, et al: Systemic
PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by
eliminating activated hepatic stellate cells. Hepatology.
64:209–223. 2016. View Article : Google Scholar :
|
|
50
|
Yang JA, Kong WH, Sung DK, Kim H, Kim TH,
Lee KC and Hahn SK: Hyaluronic acid-tumor necrosis factor-related
apoptosis-inducing ligand conjugate for targeted treatment of liver
fibrosis. Acta Biomater. 12:174–182. 2015. View Article : Google Scholar
|
|
51
|
Wang T, Wu D, Li P, Zhang K, Tao S, Li Z
and Li J: Effects of Taohongsiwu decoction on the expression of
α-SMA and TGF-β1 mRNA in the liver tissues of a rat model of
hepatic cirrhosis. Exp Ther Med. 14:1074–1080. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Feng H, Wang Y, Su J, Liang H, Zhang CY,
Chen X and Yao W: MicroRNA-148a suppresses the proliferation and
migration of pancreatic cancer cells by down-regulating ErbB3.
Pancreas. 45:1263–1271. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang K, Wong P, Salvaggio C, Salhi A,
Osman I and Bedogni B: Synchronized targeting of Notch and ERBB
signaling suppresses melanoma tumor growth through inhibition of
Notch1 and ERBB3. J Invest Dermatol. 136:464–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Humtsoe JO, Pham E, Louie RJ, Chan DA and
Kramer RH: ErbB3 upregulation by the HNSCC 3D microenvironment
modulates cell survival and growth. Oncogene. 35:1554–1564. 2016.
View Article : Google Scholar
|
|
55
|
Sayagués JM, Corchete LA, Gutiérrez ML,
Sarasquete ME, Del Mar Abad M, Bengoechea O, Fermiñán E, Anduaga
MF, Del Carmen S, Iglesias M, et al: Genomic characterization of
liver metastases from colorectal cancer patients. Oncotarget.
7:72908–72922. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shi DM, Li LX, Bian XY, Shi XJ, Lu LL,
Zhou HX, Pan TJ, Zhou J, Fan J and Wu WZ: miR-296-5p suppresses EMT
of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3
signaling. J Exp Clin Cancer Res. 37:2942018. View Article : Google Scholar : PubMed/NCBI
|
